Article Text

Download PDFPDF

Nomifensine in parkinsonism.
  1. P F Teychenne,
  2. D M Park,
  3. L J Findley,
  4. F C Rose,
  5. D B Calne


    Nomifensine, a tetrahydroisoquinolone antidepressant which facilitates dopaminergic and noradrenergic transmission, was studied in 28 Parkinsonism patients most of whom were also receiving conventional medications. Double-blind evaluations revealed a moderate therapeutic action at a mean dose level of 150 mg daily. Adverse reactions were encountered, similar to those identical by levodopa.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.